Walgreens Boots Alliance, Inc. (W8A.F)
| Previous close | 16.50 |
| Open | 16.40 |
| Bid | 15.94 x 30000 |
| Ask | 16.02 x 30000 |
| Day's range | 16.40 - 16.40 |
| 52-week range | 15.94 - 30.44 |
| Volume | |
| Avg. volume | 865 |
| Market cap | 14.269B |
| Beta (5Y monthly) | 0.79 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.92 (5.57%) |
| Ex-dividend date | 20 May 2024 |
| 1y target est | N/A |
- Business Wire
Walgreens Brand Naloxone Available Online and In Stores This Month
DEERFIELD, Ill., May 15, 2024--Walgreens today announced it is expanding access to an over the counter, life-saving medication with the launch of Walgreens Brand Naloxone HCI Nasal Spray.
- Business Wire
Walgreens Honors Veterans, Active Duty Military and Their Families with Weekend Discount for Memorial Day Friday, May 24 through Monday, May 27
DEERFIELD, Ill., May 14, 2024--To honor the service and sacrifices of Americans who served in the armed forces, Walgreens is offering a Memorial Day weekend discount to all veterans, active-duty military personnel and their immediate family members, including the families of those who lost their lives in service to their country.
- Business Wire
Walgreens and Boehringer Ingelheim Are Partnering to Improve Diversity in Clinical Trials
DEERFIELD, Ill. & RIDGEFIELD, Conn., May 02, 2024--Walgreens and Boehringer Ingelheim today announced a strategic collaboration aimed at optimizing recruitment and making clinical trials more accessible, inclusive and equitable. This collaboration will offer people an opportunity to learn about and potentially participate in an important Phase III clinical trial within the familiar and accessible environment of Walgreens pharmacies, reflecting a shared vision to expand access to healthcare and r
